Optimising the mainstreaming of renal genomics: Complementing empirical and theoretical strategies for implementation

Introduction

Genomic testing is increasingly incorporated into healthcare, including the care for patients with genetic kidney diseases [1], where it has clearly demonstrated value in terms of diagnostic utility and cost-effectiveness [2,3,4,5].

In Australia, a successful national kidney genetics collaborative, KidGen has established a network of multi-disciplinary kidney genetic clinics to support the delivery of genomic testing [1, 6]. Although this model of care has established a high diagnostic yield and clinical utility of genomic testing [6, 7], the waiting time for testing and return of results has grown, due to the recognition of the impact of genomic testing and subsequent increase in demand.

Building on formative research, we sought to address these challenges through the implementation of a Clinical Change Program in the state of Victoria [6, 7]. We developed a new hub-and-spoke delivery model for the Clinical Change Program to support broader access to genomic testing. In this program, four tertiary hospitals serve as the ‘hub’. These hubs maintain existing referral pathways and manage patients requiring multidisciplinary review while acting as central contact points for renal genomics support. They facilitate central multidisciplinary team (MDT) meetings to assist nephrologists with patient selection and result interpretation. The ‘spoke’ consists of peripheral hospital site nephrologists, who can attend central MDT meetings and -receive support from genomics champions and embedded genomics experts, allowing local nephrologists to initiate genomic testing. Genomics champions and embedded genomics experts were recruited from hospitals in Melbourne, Australia, that already offer genomic testing. In our Clinical Change Program, the genomics champions are nephrologists and renal nurses, while the embedded genomics experts include clinical geneticists and genetic counsellors.

Implementation strategies in clinical settings are frequently developed based on clinicians’ intuition. However, this approach often lacks a theoretical foundation which can lead to problems in replicability and generalisability of an intervention [8]. To address this issue, employing implementation science theory can be beneficial. By aligning clinicians’ intuition with implementation science theory, models or frameworks, complementary implementation strategies can be generated and generalised in various settings [8]. Implementation science theory, models and frameworks have been employed in genetics, and previous studies have demonstrated their value in supporting the uptake of clinical genomic testing and ensuring health services are provided and improved to meet patient needs [1, 9,10,11,12].

To investigate the mainstreaming of kidney genomics, we employed an implementation science framework, the Consolidated Framework for Implementation Research (CFIR) [13, 14], to structure an investigation into the factors influencing the Clinical Change Program’s uptake and generate implementation strategies to support nephrologists. The CFIR is a comprehensive framework, commonly used in genomic implementation research to systematically assess factors that influence the implementation of interventions in healthcare settings [15,16,17]. There are five domains: the intervention characteristics; outer setting domain; inner setting domain; characteristics of individuals; and the implementation process [13, 14].

In this study, we had three aims: i. to identify barriers to delivering the Clinical Change Program aimed at mainstreaming renal genomics, ii. to identify clinicians’ empirical implementation strategies for implementing the program, and iii. to generate theory-informed implementation strategies to support mainstreaming of kidney genomics. Empirical implementation strategies in our study refer to those informed by clinicians’ intuition and their practical clinical experiences to overcome barriers in implementing the Clinical Change Program. In contrast, theoretical implementation strategies are derived from implementation science theories, models, or frameworks.

Subjects and methods

Participants

Genomics champions and embedded genomics experts played significant roles in upskilling nephrologists to incorporate genomic testing into routine care. Specifically, they were responsible for upskilling nephrologists by attending multidisciplinary team (MDT) meetings, providing education, and ad hoc advice as required. The genomics champions and embedded genomics experts were also upskilled in kidney genomics, with increased exposure to this subspecialty and support from the Clinical Change Program and network of clinicians. They were invited to participate in semi-structured interviews at the beginning of the Clinical Change Program to investigate perceived initial barriers and enablers to the mainstreaming of renal genomics through the implementation process.

Study design and data analysis

We used a cross-sectional, qualitative study design with semi-structured interviews. The interview guide was informed by the CFIR [13, 14] and included questions such as, “In our project, is there anything particularly helpful for your work in using genomics?” to measure the inner setting domain of CFIR, and question “Before joining our project, how confident did you feel when talking about renal genomics with patients?” to measure “characteristics of individuals”. One experienced researcher (LC) conducted the interviews either online or in person, according to participant preference. Interviews lasted 25–45 min. All interviews were audio recorded and transcribed verbatim for data analysis. The interviews were conducted between April and October 2023.

Transcripts were analysed using both inductive and deductive approaches. First, to identify barriers and enablers perceived by clinicians, two implementation scientists (LC and SB) extracted barriers and enablers to the mainstreaming of renal genomics through the Clinical Change Program. Three transcripts were randomly selected and coded independently. Extracted barriers and enablers were discussed to reach a consensus during regular fortnightly meetings. LC then completed the extraction of the barriers and enablers from the remaining transcripts, with ongoing discussions with SB to finalise the full list of barriers and enablers.

These barriers informed the development of theoretical implementation strategies, and enablers informed the identification of empirical implementation strategies. The enablers identified by genomics champions and embedded genomics experts were defined as ‘empirical implementation strategies’ in this study as they were based on the genomics champions’ and embedded genomics experts’ clinical experience. To complement these experiential strategies, ‘theoretical implementation strategies’ were developed by mapping interview data onto implementation science framework. Figure 1 outlines the process of generating these strategies for mainstreaming renal genomics through the Clinical Change Program.

Fig. 1: Process for developing implementation strategies.
figure 1

This figure illustrates how implementation strategies were developed using ERIC for mainstreaming the renal genomics.

Full size image

To develop theoretical implementation strategies, all identified barriers were mapped onto CFIR constructs to facilitate the next step using the CFIR-ERIC matching tool [18]. This tool comprises two components: (1) CFIR, identifying barriers; and (2) Expert Recommendations for Implementing Change (ERIC), generating implementation strategies. This analysis was conducted collaboratively by two implementation scientists (LC and NK) through four iterative discussions, reaching a consensus on CFIR constructs. After employing the CFIR-ERIC matching tool, the tool generated a list of theoretical implementation strategies to address the barriers. LC and NK then reviewed the list to select pertinent implementation strategies capable of addressing the challenges articulated by genomics champions and embedded genomics experts.

Second, to generate empirical implementation strategies, two implementation scientists (LC and NK) cross-referenced barriers with enablers to identify potential solutions from the enablers that could address the barriers raised by genomics champions and embedded genomics experts. These empirical enablers were based on genomics champions and embedded genomics experts’ reflections on their clinical experience. After achieving a consensus on the list of empirical enablers through two discussions, LC – in discussion with NK and SB – mapped these empirical enablers with ERIC strategies to conceptualise them and subsequently aligned the empirical and theoretical implementation strategies to generate a complementary set of implementation strategies.

Ethics approval

This study was approved by the Human Research Ethics Committee of the Melbourne Genomics Health Alliance (Ethics approval number: HREC/80793/MH-2021).

Results

A total of 14 genomics champions and embedded genomics experts from four hospital sites were interviewed: nephrologists (n = 3), clinical geneticists (n = 2), genetic counsellors (n = 6) and renal nurses (n = 3) (Table 1). Data analysis was conducted concurrently with the interviews, and after 10 interviews no new data was identified. A further four interviews were conducted to ensure a sufficient sample size had been reached [19].

Table 1 Demographic information.
Full size table

Barriers to delivering the Clinical Change Program to mainstream genomics

A total of 102 quotes were extracted, identifying 34 barriers. The most frequently mentioned barriers were that nephrologists lacked time to incorporate genomic information into routine care and did not feel confident in discussing genomic testing with patients. The other frequently mentioned barriers were about the operation of the Clinical Change Program, such as role clarity for genomics champions and embedded genomics experts. Specifically, nephrologists and renal nurses, serving as genomics champions, were unclear about their responsibilities in delivering the Clinical Change Program. Meanwhile, geneticists and genetic counsellors were not performing their typical roles as they would in a traditional genetics setting. Instead, their roles were more varied and extended beyond their usual roles. Also, limited dissemination of the new model was highlighted as a significant barrier, potentially hindering its mainstream adoption in nephrology departments across the state. Another barrier related to the sustainability of the Clinical Change Program with participants concerned about the role of genomics champions and embedded genomics experts after completion of the Clinical Change Program.

Specific barriers relevant to the initial stages of the program were identified. For example, low engagement among nephrologists was noted at the beginning of the Clinical Change Program’s implementation. Other perceived barriers included integrating the Clinical Change Program into existing clinical workflows, a lack of working space for genetic counsellors within nephrology departments, and the additional workload for renal nurses to prepare documents for case review in MDT meetings and gather patients’ information for genomic testing. Table 2 shows the full list of perceived barriers at the beginning of the Clinical Change Program.

Table 2 Barriers to the delivery of the Clinical Change Program.
Full size table

Empirical implementation strategies to mainstream genomics in nephrology

A total of 133 quotes were extracted from the interviews, representing 26 empirical enablers that could facilitate the delivery of the new model of care. The quotes representing empirical enablers were cross-referenced with barriers to identify potential solutions (Fig. 1). These empirical enablers were coded to the ERIC to conceptualise them as empirical implementation strategies. The mapping resulted in 25 empirical implementation strategies. The most frequently mentioned empirical strategies included ‘promote network weaving’, ‘create a learning collaborative’, ‘change physical structure and equipment’ and ‘provide clinical supervision’. Supplementary Table 1 lists the full set of empirical implementation strategies addressing the identified barriers.

Complimentary theoretical implementation strategies to support mainstream genomics in nephrology

After mapping all barriers onto CFIR constructs to conceptualise the problems, the CFIR-ERIC matching tool was employed to generate theoretical implementation strategies to complement the empirical implementation strategies. This mapping resulted in 35 theoretical implementation strategies, such as ‘identify and prepare champions’, ‘facilitation’, ‘create a learning collaborative’ and ‘capture and share local knowledge’.

When we aligned the two sets of strategies, there were some overlaps between the empirical and theoretical implementation strategies. As shown in Fig. 2, empirical implementation strategies could be supplemented by the theoretical implementation strategies. A total of 21 overlapped strategies, such as ‘promote network weaving’ and ‘create a learning collaborative’, were generated from both clinicians’ experience and implementation theory. Four empirical implementation strategies, such as ‘provide clinical supervision’ and ‘create new clinical teams’, were not identified in theory, while 14 theoretical implementation strategies, such as ‘promote adaptability’, ‘conduct local consensus discussions’ and ‘conduct educational outreach visits’, were not identified based on clinical experiences.

Fig. 2
figure 2

Empirical implementation strategies and theoretical implementation strategies.

Full size image

Figure 3 shows nine clusters of implementation strategies [20] and ten groups of barriers. It illustrates how the identified ‘barriers’ can be addressed by empirical and theoretical implementation strategies. Specific implementation strategies and barriers can be found in Supplementary Tables 2 and 3. For example, in relation to the complexity of genomic testing, the most common challenge nephrologists reported was time constraints during patient consultations. Incorporating genomics requires additional time to discuss the testing with patients and interpret test results. It can be difficult to cover large amounts of information about both nephrology and genomics in the consultation. To address this, clinicians suggested implementation strategies to ‘identify and prepare champions’ such as genetic counsellors to assist with patient communication and result interpretation outside of renal consultations. Complementary theoretical implementation strategies suggest nephrologists may consider such as ‘capture and share local knowledge’ from implementing sites to learn how other clinicians manage this challenge. Additionally, the theoretical implementation strategy, ‘promote adaptability’, indicated that the Clinical Change Program needs to be further enhanced to adapt to the identified barriers.

Fig. 3
figure 3

How empirical and theoretical implementation strategies can address the barriers to support the mainstreaming of renal genomics. This figure illustrates how empirical and theoretical implementation strategies shown in the middle bars can address the barriers shown in the right bars.

Full size image

For the challenges related to the initial operationalising of the program to mainstream genomics, some issues such as unclear responsibilities of genomics champions and embedded genomics experts for supporting the mainstreaming of the renal genomics and low awareness of the Clinical Change Program among clinicians were identified. To clarify the genomics champions and embedded genomics experts roles, while there were several empirical implementation strategies such as ‘purposely reexamine the implementation’, theoretical implementation strategies provided additional lenses to address the problem such as ‘develop and implement tools for quality monitoring’ for the process of mainstreaming. To increase awareness of the Clinical Change Program, empirical implementation strategies like ‘promote network weaving’ and ‘create a learning collaborative’ were proposed. In addition, the theoretical implementation strategy suggested ‘organise clinician implementation team meetings’ to support clinicians mainstreaming renal genomics to reflect on the implementation effort and share learning experiences.

Discussion

To improve equitable and timely access to genomic testing, we have implemented a Clinical Change Program to mainstream genomic testing in nephrology departments in Australia. However, an evidence-based healthcare intervention alone is insufficient to guarantee its successful implementation, as various factors in real-world settings will influence uptake [21]. Implementation science provides rigorous approaches to explore these factors and generate strategies to address the problems. By employing an implementation science framework, CFIR, we not only identified barriers reported in previous studies that hinder the mainstreaming of genomic testing in clinical practice [22, 23], but also uncovered additional barriers in real-world implementation that were previously overlooked. Subsequently, we used the CFIR-ERIC matching tool to map out the clinicians’ strategies to address the barriers to mainstreaming renal genomics. Various empirical implementation strategies were proposed by clinicians and implementation science frameworks generated complementary strategies to support nephrologists in incorporating genomics in renal healthcare.

The numerous ‘barriers’ identified demonstrate how challenging it is to incorporate genomics into nephrologists’ routine clinical practice. Our findings also indicated that the challenges stem from both the complexity of using genomics in renal healthcare and from trying to integrate a new model of care into routine care.

The barriers related to the complexity of genomic testing, such as inadequate training for nephrologists to incorporate genomic testing in standard care, translating genomic testing into personalised clinical management and the lack of necessary infrastructure for routine implementation, have been reported in previous studies [22, 23]. Clinicians have strategies to solve these problems, but they may also benefit from incorporating theoretical implementation strategies [8]. Our results confirmed that empirical implementation strategies can be complemented by theoretical implementation strategies. For example, one barrier was that nephrologists felt lack of confidence in incorporating genomics into their standard practice, which was also identified in a previous study [6]. While clinicians came up with the empirical implementation strategy such as ‘provide clinical supervision’ and ‘develop educational materials’, there were other complimentary theoretical implementation strategies such as ‘create a learning collaborative’ to foster a collaborative learning environment, ‘identify and prepare champions’ to help with upskilling clinicians, and ‘facilitation’ for interactive problem solving and support.

The mainstreaming of genomic testing is hindered not only by barriers related to its complexity, but also how frontline clinicians integrate genomic testing into their standard workflow [24]. This compounded challenge highlights the need for effective and rigorously tested new models of care to incorporate genomic testing into clinical practice. As we implement the Clinical Change Program to achieve this goal, it is crucial to understand the barriers related to the implementation and to identify strategies to address them. This understanding would accelerate the mainstreaming of genomic testing in nephrology departments.

Identified barriers, such as how to incorporate genomic testing into the current clinical workflows and how to create a logistically simple program for mainstreaming, provide additional perspectives to understand the challenges of incorporating genomic testing in real-world contexts. The incorporation of genomic testing requires a holistic approach that involves a dynamic interaction among health professionals, patients and the health system [25]. Therefore, it is important to develop implementation strategies with efforts from different stakeholders and understand the barriers to its implementation. To address these barriers, we employed implementation science approaches to generate theoretical implementation strategies in addition to empirical implementation strategies, as theory-driven strategies can offer additional benefits to promote clinical intervention use and improvement [8].

However, this study has limitations. Given that our findings were based on baseline interviews, the Clinical Change Program was not fully operationalised, and there were limited opportunities to provide feedback on its functioning. Consequently, additional barriers and implementation strategies may not have been identified at the baseline. Further investigation is needed to assess and enhance our Clinical Change Program, and follow-up data should be collected to identify additional potential barriers and implementation strategies as the program is rolled out. Also, the barriers reported in this paper were perceived by genomics champions and embedded genomics experts. These may differ from those experienced by nephrologists when incorporating genomic testing in routine practice. Therefore, future work is needed to explore nephrologists’ perspectives. Additionally, since the study was carried out in the nephrology setting, future studies should investigate the feasibility and effectiveness of our approach in other clinical and healthcare settings as result may not be generalisable. Furthermore, addressing the various challenges in mainstreaming genomic testing in clinical practice requires collaborative efforts among patients, health professionals, researchers and health system to mainstream genomic testing successfully.

In conclusion, our study provided a novel approach to demonstrate how implementation science frameworks can support clinicians in identifying barriers to mainstreaming renal genomics, as well as developing both empirical and theoretical implementation strategies to support mainstreaming. These barriers and implementation strategies identified may serve as valuable references for future studies as the model of care evolve and be applied in other settings.

Related Articles

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

Integrated proteogenomic characterization of ampullary adenocarcinoma

Ampullary adenocarcinoma (AMPAC) is a rare and heterogeneous malignancy. Here we performed a comprehensive proteogenomic analysis of 198 samples from Chinese AMPAC patients and duodenum patients. Genomic data illustrate that 4q loss causes fatty acid accumulation and cell proliferation. Proteomic analysis has revealed three distinct clusters (C-FAM, C-AD, C-CC), among which the most aggressive cluster, C-AD, is associated with the poorest prognosis and is characterized by focal adhesion. Immune clustering identifies three immune clusters and reveals that immune cluster M1 (macrophage infiltration cluster) and M3 (DC cell infiltration cluster), which exhibit a higher immune score compared to cluster M2 (CD4+ T-cell infiltration cluster), are associated with a poor prognosis due to the potential secretion of IL-6 by tumor cells and its consequential influence. This study provides a comprehensive proteogenomic analysis for seeking for better understanding and potential treatment of AMPAC.

Engineering bone/cartilage organoids: strategy, progress, and application

The concept and development of bone/cartilage organoids are rapidly gaining momentum, providing opportunities for both fundamental and translational research in bone biology. Bone/cartilage organoids, essentially miniature bone/cartilage tissues grown in vitro, enable the study of complex cellular interactions, biological processes, and disease pathology in a representative and controlled environment. This review provides a comprehensive and up-to-date overview of the field, focusing on the strategies for bone/cartilage organoid construction strategies, progresses in the research, and potential applications. We delve into the significance of selecting appropriate cells, matrix gels, cytokines/inducers, and construction techniques. Moreover, we explore the role of bone/cartilage organoids in advancing our understanding of bone/cartilage reconstruction, disease modeling, drug screening, disease prevention, and treatment strategies. While acknowledging the potential of these organoids, we discuss the inherent challenges and limitations in the field and propose potential solutions, including the use of bioprinting for organoid induction, AI for improved screening processes, and the exploration of assembloids for more complex, multicellular bone/cartilage organoids models. We believe that with continuous refinement and standardization, bone/cartilage organoids can profoundly impact patient-specific therapeutic interventions and lead the way in regenerative medicine.

Responses

Your email address will not be published. Required fields are marked *